Latest Headlines

Latest Headlines

U.K. starts work on $64M biologics manufacturing center

The U.K. is investing £38 million in its National Biologics Manufacturing Centre, part of the country's "High Value Manufacturing Catapult" effort started several years ago to increase its presence in biologics.

Kyowa Hakko Kirin finishes $60M biologics API plant

Japanese drugmaker Kyowa Hakko Kirin, which develops its own drugs and is in a partnership with Fuji to make biosimilars, has completed construction on a new active pharmaceutical plant for biologics.

Sanofi, UCB team up in $138M deal aimed at tackling biologic blockbusters

Sanofi is joining forces with UCB to study new small-molecule approaches to treating inflammatory conditions like arthritis, looking for an easier form of administration to some of the blockbuster injected biologics that dominate the field. The pharma giant is ready to spend more than $138 million for a package of milestones and an upfront payment to UCB in exchange for the partnering arrangement with its NewMedicines research arm.

Obama administration looks to chop back market exclusivity for biologics

One of the signal achievements for the biotech industry in the Affordable Care Act was a provision granting 12 years of market exclusivity to biologics. The decade-plus period of protection against generic competition ensured that biologics would remain center stage in the R&D world, especially as Big Pharma tumbled over the patent cliff as it tried to rethink its megablockbuster-sized budgets for drug development.

Pfizer and MIT are looking for more efficient biologics manufacturing

Pfizer is partnering with the Massachusetts Institute of Technology (MIT) to see if they can find new processes that will cut costs and increase efficiency, the Boston Business Journal reports.

Cytovance expands its biologics manufacturing and warehousing operations

With the the coming entry of biosimilars in the U.S. and expansion of that market in Europe, biologic drugs are going to be in greater demand, as will the contract manufacturers who can supply the cell lines and special services needed to get them to market. Okalahoma-based Cytovance Biologics is joining a number of CMOs that are adding capacities to tap that growth.

Lonza's pharma unit sales suffer as it closes U.S. biologics plant

Swiss drug ingredient and chemical maker Lonza has reorganized its drug ingredient and custom pharma manufacturing units and is closing a U.S. plant to reduce costs, but so far the move has resulted in lower sales in pharma.

Pall moves into single-use bioreactors with deal to buy ATMI LifeSciences

Pall, which has been supplying drug manufacturers with filtration equipment for a long time, has decided to broaden its place in the biopharma manufacturing equipment industry, adding single-use bioreactors and supplies with a deal to buy a division of ATMI.

$1B deal pushes GE further into biologics manufacturing

GE Healthcare is tapping further into the global buildup in biologics manufacturing capacity with a $1 billion deal that gives it three businesses that Thermo Fisher Scientific has decided to unload, including its HyClone cell culture media and sera operation.

Alvogen makes a $250M biosimilars investment in Iceland

Biosimilars are expected to become a significant piece of the generics business worldwide, and Alvogen is spending $250 million to build a facility in Iceland to develop and manufacture biosimilars.